Interim results for the six months ended 30 June 2023
September 29, 2023 16:30 ET
|
Biodexa Pharmaceuticals PLC
29 September 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended 30 June 2023 Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage...
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)
September 21, 2023 08:30 ET
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at...
Global Orphan Drugs Market Research Report 2023
September 19, 2023 05:38 ET
|
Research and Markets
Dublin, Sept. 19, 2023 (GLOBE NEWSWIRE) -- The "Orphan Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global orphan drugs market is expected to grow...
Infant Bacterial Therapeutics AB (publ) Interim report January 1 - June 30, 2023
August 25, 2023 02:30 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO Our Phase-III study, the largest of its kind ever conducted, is progressing across 88 hospitals in ten countries. We have now recruited 85% of the patients (1824 out of the...
Infant Bacterial Therapeutics AB (publ), Delårsrapport 1 januari – 30 juni 2023
August 25, 2023 02:30 ET
|
Infant Bacterial Therapeutics AB
VD Kommentarer Vår Fas III-studie, den största studien av sitt slag som någonsin genomförts, fortskrider på 88 sjukhus och i tio länder. Vi har nu rekryterat 85% av patienterna (1824 av de...
Orphan Drugs and Rare Diseases Conference: Life-saving Therapies, Critical Issues, and Strategies to Enhance Orphan Drug Development in near future (London, United Kingdom - October 9-10, 2023)
August 14, 2023 04:13 ET
|
Research and Markets
Dublin, Aug. 14, 2023 (GLOBE NEWSWIRE) -- The "Orphan Drugs and Rare Diseases Conference" conference has been added to ResearchAndMarkets.com's offering. The 4th Annual Orphan Drugs and Rare...
Over 1000 Orphan Drugs in Clinical Trials in the US - Eylea, Actimmune, Ravicti Among Key Approved Therapies
August 07, 2023 06:43 ET
|
Research and Markets
Dublin, Aug. 07, 2023 (GLOBE NEWSWIRE) -- The "US Orphan Drugs Market, Drugs Sales, Price, Dosage & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. ...
Avexitide: A 31-amino Acid Peptide that Selectively Targets and Blocks GLP-1 Receptors - Emerging Drug Insights and Market Forecasts, 2019-2022 & 2023-2032
August 01, 2023 06:28 ET
|
Research and Markets
Dublin, Aug. 01, 2023 (GLOBE NEWSWIRE) -- The "Avexitide Emerging Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering. "Avexitide Emerging...
New number of shares and votes in IBT
July 31, 2023 04:00 ET
|
Infant Bacterial Therapeutics AB
The number of shares and votes in Infant Bacterial Therapeutics AB (publ) has changed due to the recently completed rights issue (for further information, see the company’s press release on 4 July...
Nytt antal aktier och röster i IBT
July 31, 2023 04:00 ET
|
Infant Bacterial Therapeutics AB
Antalet aktier och röster i Infant Bacterial Therapeutics AB (publ) har förändrats med anledning av den nyligen genomförda företrädesemissionen (för mer information, se bolagets pressmeddelande den 4...